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Atypical hemolytic uremic syndrome (aHUS) is associated
with complement alternative pathway defects in over half
the cases. Point mutations that affect complement surface
regulation are common in factor H (CFH); however,
sometimes individuals have null mutations in heterozygosis.
The latter are difficult to identify, although a consistently low
plasma factor H (fH) concentration is suggestive; definitive
proof requires demonstration that the mutant sequence is
not expressed in vitro. Here, novel reagents and assays that
distinguish and individually quantify the common factor
H-Y402H polymorphic variants were used to identify alleles
of the CFH gene, resulting in low or null expression of
full-length fH and also normal or increased expression of the
alternative splice product factor H-like-1 (FHL-1). Our assay
identified three Y402H heterozygotes with low or absent
fH-H402 but normal or increased FHL-1-H402 levels in a
cohort of affected patients. Novel mutations explained the
null phenotype in two cases, which was confirmed by family
studies in one. In the third case, family studies showed that a
known mutation was present on the Y allele. The cause of
reduced expression of the H allele was not found, although
the data suggested altered splicing. In each family,
inheritance of low expression or null alleles for fH strongly
associated with aHUS. Thus, our assays provide a rapid
means to identify fH expression defects without resorting to
gene sequencing or expression analysis.
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Hemolytic uremic syndrome (HUS), characterized by the triad
of thrombocytopenia, microangiopathic hemolytic anemia,
and acute renal failure, is one of the commonest causes of
renal failure in children.1 When not associated with diarrheal
illness, or when recurrent, the disease is considered atypical
HUS (aHUS), accounting for o10% of all HUS cases. aHUS
has a poor prognosis; it is fatal in up to 25% in the acute phase
and 50% of survivors require ongoing renal replacement
therapy.2 Numerous environmental precipitants of aHUS have
been described, including infections,3,4 tumors,5 pregnancy,6
drugs,7 and metabolic syndromes.8 In some families, both
autosomal recessive and autosomal dominant inheritance
modes were seen.9,10 Research over the last decade has
identified mutations in genes encoding complement regulators
or components in 50% of aHUS cases; these include factor H
(fH; reviewed in Rodriguez de Cordoba et al.11), membrane
cofactor protein,12 factor I,13 C3,14 and factor B,15 provoking
the suggestion that aHUS is a disease caused by dysregulation
of the alternative pathway (AP) of complement.15 Mutations
in the gene encoding fH (CFH) are the most frequent asso-
ciation with aHUS, with over 100 different mutations
identified.16 The genetic basis of about half of aHUS cases in
all cohorts remains undefined, provoking a search for other
causative factors.
fH, a 150-kDa serum glycoprotein, regulates the AP of
complement by acting as cofactor for factor I-mediated
proteolytic inactivation of C3b, competing with factor B for
C3b binding, and accelerating decay of the C3 convertase.11
fH is the key fluid-phase regulator of the AP, but also
regulates AP activation on host cells and exposed basement
membranes by binding glycosaminoglycans through its
C-terminal domain (short consensus repeats (SCRs) 19 and
20).17 The complement regulatory domain (SCRs 1–4) then
provides regulation on the surface. Mutations in CFH have
been described in multiple cohorts (collated on http://
www.fh-hus.org) and account for some 30% of aHUS cases.16
The vast majority are heterozygous, either premature stop
codons or single amino acid changes. Incomplete penetrance
has been described in all series, suggesting that aHUS is multi-
factorial, resulting from a combination of environmental
triggers that injure endothelial cells, activate complement, and
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precipitate disease in genetically susceptible individuals.18
Most fH mutations associated with aHUS are in the
C-terminal SCRs and cause decreased binding of fH to
glycosaminoglycans on endothelial cells and basement mem-
branes.19 This will cause impaired regulation of AP ampli-
fication at these sites, whereas fluid-phase regulation is
unimpaired. In a minority of aHUS cases, null mutations are
found, resulting in heterozygous or, rarely, homozygous
deficiency of fH.20 Although patients with null mutations in
heterozygosity will usually have low plasma levels of fH,20 the
large variability in fH concentrations in normal individuals
makes it difficult or impossible to identify cases simply
by measuring fH levels in plasma. Definitive proof that
a particular mutant is null has previously required gene
sequencing and the demonstration that the mutant cDNA,
transfected into an appropriate cell line, failed to make
fH protein.21,22 Methods for measuring expression from
individual fH alleles would facilitate identification and
assignation of null alleles without the need for laborious
cloning and expression.
The Y402H polymorphism of fH is strongly linked to
age-related macular degeneration.23 In Caucasians, the allele
frequency (Y:H) is approximately 2.5:1 in healthy individuals;
hence, over 40% of Caucasians are Y402H heterozygous.
This polymorphism therefore represents a useful ‘marker’
for individual CFH alleles. We have previously reported a
monoclonal antibody (mAb) specific to fH-H402.24 Here,
we describe production of a mAb specific to fH-Y402 and
the development of assays for independent quantification
of the Y402H variants. Although the Y402H polymorphism
has no apparent direct link to aHUS, application of the new
assays to aHUS families enabled us to identify, characterize,
and confirm new CFH alleles associated with low or no
expression of full-length fH, but normal or increased
expression of the alternative splice product of the CFH gene,
factor H-like-1 (FHL-1). We show that these low or no
expression alleles for fH conferred strong predisposition to
aHUS. These novel tools will not only help in identification
of the molecular basis of disease in patients with aHUS, but
also aid in the prediction of risk in their relatives.
RESULTS
Variant-specific mAb permit independent measurement of
CFH allele products
The fH-H402-specific mAb was described previously;24 for
this study a mAb specific for the Y402 variant was needed.
From 10 fusions, two mAb were obtained that selectively
bound fH-Y402; one immunoglobulin (Ig) G1 isotype, the
other IgM, designated as MBI-6 and MBI-8, respectively.
The IgG1 mAb MBI-6 was expanded and purified; specificity
for fH-Y402 was confirmed using enzyme-linked immuno-
sorbent assay (ELISA; Figure 1a) and western blot
(Figure 1b), confirming that it reacted exclusively with
fH-Y402. Dot blotting of plasma from donors of known
Y402H polymorphic status confirmed specificity for fH-Y402
(Figure 1c). The fH-H402-specific mAb MBI-7 is included as
an additional control and to demonstrate the utility of these
mAb for independently identifying the presence of these two
isoforms of fH. Affinities of MBI-6 for fH-Y402 and fH-H402
were assessed by surface plasmon resonance; the mAb failed
to bind fH-H402, but bound fH-Y402 with a KD¼
15.2 nmol/l (w2¼ 8.96), confirming the high affinity and
absolute specificity of the mAb.
ELISA for quantification of each variant in plasma was
developed using the variant-specific antibodies. Both the
variant-specific and total fH assays measure the combined
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Figure 1 |Monoclonal antibody (mAb) MBI-6 specifically
detects factor H (fH)-Y402. (a) Enzyme-linked immunosorbent
assay with each fH variant directly immobilized on plate; OX-24
detected both Y402 (closed squares) and H402 (closed circles),
whereas MBI-6 detected only Y402 (open squares) and failed
to detect H402 (open circles). (b) Western blot showing the
detection of fH variants using Y402-specific (MBI-6; left) and
H402-specific (MBI-7; right) mAb. The same amount of each
protein was loaded in each lane. MBI-6 detected only the Y402
variant and MBI-7 only the H402 variant. (c) Dot blot in which 5 ml,
10ml, or 20 ml aliquots (from left to right) of 10-fold diluted plasma
from YY402 and HH402 homozygous donors were spotted on the
membrane and probed with either Y402-specific (MBI-6; top),
non-selective (OX-24; middle), or H402-specific (MBI-7; bottom)
mAb.
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levels of fH and FHL-1, the latter an alternative splice
product of the CFH gene comprising the first seven SCRs of
fH and thus sharing the Y402H polymorphism (in SCR7),
but neither assay detects any of the reported fH-related
proteins (FHR-1, -2, -3, -4, -5). The plasma concentrations
of fH and FHL-1 correlate in individual donors with
FHL-1 concentrations 10–50 fold lower than fH in normal
individuals.11,25
The calculated assay detection limit was 0.01mg/l and the
working range was 0.02–0.3mg/l. Assay performance was
assessed by taking multiple measures from independently
diluted aliquots of the same samples. Within-assay precision
was 1.3–15.5% across the working range with an average of
5.5% for fH-Y402 measurement, and 1.4–16.8% with an
average of 5.6% for fH-H402 measurement. Between-assay
precision was 6.7–17.6% with an average of 11.9% for
fH-Y402 measurement, and 5.1–12.2% with an average of
9.7% for fH-H402 measurement.
Measurement of fH variants in healthy donors and aHUS
patients
To confirm assay performance and establish normal range
(nr), concentrations of fH variants were measured using
ELISA in 46 healthy control donors (mean age 42.2±13.8
years, range 25–66 years; 63% female; 21 YY402, 5 HH402,
20 YH402; Y402:H402 allele ratio 0.67:0.33). Total fH was
calculated both by summing the amounts of each variant
and by using a non-selective fH assay. Values obtained
by summing variant concentrations closely matched fH
values obtained in the non-selective assay, confirming the
validity of the variant-specific assays (for the whole
cohort, 257.5±89.8mg/l from sum of assays and
263.3±69.4mg/l from total fH assay). The nr (mean±2 s.d.)
was 77.9–437.1mg/l in the summed assay and 124.4–402mg/l
in the total fH assay, illustrating the broad range in plasma fH
levels in this normal population. Values for plasma fH in
our assays are lower than those quoted in past studies,
a consequence of recalibration based on accurate extinction
coefficients calculated as described.24 Mean total fH was not
different between the three groups (YY402, 267.2±66.7mg/l;
YH402, 250.9±56.9mg/l; HH402, 214.7±81.5mg/l). In
heterozygote controls, variant levels were not significantly
different. Importantly, no heterozygote control had selective
low or no expression of one allele.
From the Spanish aHUS cohort, 48 individuals hetero-
zygous for the Y402H polymorphism were identified
and tested in the Y402H variant-specific assays (Figure 2).
Three unrelated individuals (Hus29, Hus90, and Hus169)
were identified, in whom expression of the H402 allele
was very low compared with the Y402 allele. fH level in index
case Hus90 was 109mg/l (Y402, 100mg/l; H402, 9mg/l), in
case Hus169 was 73mg/l (Y402, 60mg/l; H402, 13mg/l), and
in case Hus29 was 148mg/l (Y402, 130mg/l; H402, 18mg/l).
Total fH level fell below the calculated nr (mean±2 s.d.) only
for Hus169; in the others, total fH levels were in the lower
quartile of the nr.
Index case Hus29 had been reported before as a carrier
of the fH mutation R1210C, a known aHUS-associated
mutation causing disulfide bonding of fH to albumin in
plasma;19,26 the albumin-bound protein is present in plasma
in normal amounts, retains the capacity to inhibit fluid-
phase complement activation, but has impaired binding to
surfaces. All exons in CFH had been sequenced in Hus29 and
no other mutations had been found. Eight family members,
all healthy, were available, of whom five carried the R1210C
mutation (Figure 3a). Father, aunt, and paternal great-
grandfather were R1210C carriers, Y402 homozygous with
normal plasma fH levels, demonstrating that R1210C was
on the Y402 allele. Paternal grandfather, a R1210C carrier,
was Y402H heterozygous with normal plasma fH levels and
similar levels of fH-H402 and fH-Y402. Mother, a H402
homozygote, did not carry the R1210C mutation and had
low plasma fH levels. Both the index case and her sister were
Y402H heterozygous, and carried the R1210C mutation;
however, whereas the sister had normal plasma fH levels with
similar amounts of each variant, the index case had low total
fH and very low fH-H402 levels in plasma. Western blot of
plasma fH in the index case and her sister using the fH-H402-
specific mAb demonstrated differential expression of the two
maternal H402 alleles, 12% of control levels in the index case
by densitometry, and normal expression (90% of control) in
her sister (Figure 4). Because the R1210C mutation was on
the Y402 allele, no high molecular weight albumin–fH
complex was detected by this H402-specific mAb. Expression
of the H402 allele of the alternative splice product of CFH,
FHL-1, was increased fivefold (by densitometry) in the index
case, but not increased compared with controls in her sister
(Figure 4). Analysis of the promoter and intronic sequences
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Figure 2 |Measurement of Y402 and H402 variants of factor H
(fH) in atypical hemolytic uremic syndrome (aHUS) patients
heterozygous for the Y402H polymorphism. Ratios of
concentrations of fH-Y402 and fH-H402 were calculated for each
individual and plotted on the graph. For the majority, the ratio
was close to 1. For three unrelated individuals (Hus29, Hus90, and
Hus169), the concentration of fH-H402 was very low compared
with fH-Y402 in that individual, giving high ratios, apparent in
the figure.
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Figure 3 | Family studies in atypical hemolytic uremic syndrome (aHUS) pedigrees. Circles represent females, squares males; closed
symbols are aHUS cases, open symbols healthy relatives, crossed-through symbols represent deceased relatives. Numbers within a symbol
provide the case number. Total factor H (fH; mg/l) and Y402H status, where available, are shown below symbols; concentrations of Y402 and
H402 variants in heterozygotes are shown below the brackets. Heavy dots indicate that the individual is a carrier for the stated mutation.
(a) Pedigree Hus29; index case H29 is Y402H heterozygote expressing very low levels of the H402 allele, and a carrier of the R1210C
mutation inherited from her father (F). Mother (M), a H402 homozygote, does not carry the R1210C mutation but had low plasma fH levels.
The healthy sister, also Y402H heterozygote and R1210C carrier, expresses normal levels of the H402 allele. (b) Pedigree Hus90; index case
H90 is Y402H heterozygote expressing very low levels of the H402 allele, and a carrier of the C853R mutation, shared with one daughter and
a niece, both healthy. The same niece and his other daughter are Y402H heterozygotes expressing very low levels of the H402 allele.
(c) Pedigree Hus169; index case H169, is Y402H heterozygote expressing very low levels of the H allele, and a carrier of the C1218R mutation.
Levels of the Y402 allele were also low in this individual.
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within the gene has so far not revealed any genetic variation
that could explain increased expression of FHL-1.
Index case Hus90 also had very low levels of fH-H402 in
plasma (Figure 3b). Western blot with fH-H402-specific
antibodies showed complete absence of fH-H402 but normal
amounts of FHL-1-H402 (Figure 4), suggestive of a null
mutation in the H402 allele downstream of SCR7. Sub-
sequent CFH sequencing revealed the presence in hetero-
zygosity of a novel mutation (C853R; SCR14). Hus90 had
three deceased affected siblings; two died during infancy and
their mutation status is unknown, whereas the third, though
deceased, is an obligate carrier of the C853R mutation
because one of his two children is a carrier. This niece of the
index case and one of his two daughters, were the only
carriers of the C853R mutation in the next generation; both
were Y402H heterozygous and, like the index case, these
individuals had very low plasma levels of the H402 allele by
ELISA (Figure 3b). Western blotting confirmed complete
absence of fH-H402 and normal expression of FHL-1-H402,
as in the index case (Figure 4). The other daughter and two
nephews of the index case were also tested and all were Y402
homozygous, non-carriers with normal plasma fH levels.
Segregation analysis in this pedigree confirmed that the H402
allele carried the C853R mutation; likely a null mutation
because the cysteine residue is essential for correct folding
of SCR14.
Index case Hus169 was also selected for low plasma
fH-H402 level. Subsequent CFH sequencing analysis revealed
the presence in heterozygosity of a novel mutation (C1218R)
in SCR20 (Figure 3c). Western blotting with the H402-
specific mAb revealed the absence of fH-H402 but normal
levels of FHL-1-H402, as in the Hus90 pedigree (Figure 4).
The plasma concentration of fH-Y402 was low at 60 mg/ml;
however, this concentration, from a single allele, is well
within the broad nr for fH noted above (78–437 mg/ml from
two alleles); these data further emphasize the importance
of allele-specific quantification to detect occult null or low
expression alleles of fH.
DISCUSSION
CFH mutations in aHUS are usually near the C-terminus
(50% in SCRs 19/20), present in heterozygosity and cause
impaired surface protection from complement activation.16,27
In these cases, plasma fH levels are unaffected, and plasma
fH is a mixture of mutant and normal protein. In a minority
of reported aHUS cases, the CFH mutation causes very
low or absent expression from that allele,20 usually identified
because of reduced fH levels in plasma. However, identifica-
tion based on fH levels is unreliable not only because of the
noted large variability in the normal population, but also
because factors such as age and smoking behavior influence
fH levels in plasma.28
We generated mAb specific for the Y402H polymorphic
variants of fH and FHL-1 to identify and quantify expression
in macular degeneration, where the H402 allele is a major
risk factor.21,22 This polymorphism has not been linked to
aHUS; nevertheless, we reasoned that the mAb and assays
would enable us to independently quantify expression from
normal and mutant alleles in aHUS, facilitating rapid
discovery of null mutations. We, here, describe the use of
these mAb to identify in families with a HUS the presence
of null or low expression alleles for full-length fH that are
associated with disease. In each of the families described,
disease was clearly associated with the inheritance of a
previously unidentified CFH low or no expression allele
revealed by the new assays.
In Hus90 and Hus169, the mutations responsible for low
expression of fH-H402 were subsequently identified as novel
loss of cysteine mutations in SCR14 (C853R) and SCR20
(C1218R), respectively. Accumulated data on fH mutations
suggest that loss of cysteine mutations in fH are null because
they disrupt SCR structure (http://www.fh-hus.org). Indeed,
western blotting of plasma from Hus90 and Hus169, with
fH-H402-specific mAb confirmed the complete absence of
fH-H402, but normal expression of FHL-1 from this allele.
Unhindered expression of FHL-1-H402 from the mutated
gene explains the traces of fH-H402 reactivity detected in
the H402-specific ELISA; all three ELISA used in the study
utilize detection mAb that bind in SCR1–7, shared by fH
and FHL-1, and thus detect both. Others have reported that
null mutations distal to SCR7 permit normal expression of
FHL-1,21,22 whereas null mutations in the shared SCRs cause
loss of both proteins.29 Indeed, the differential effects on
expression of fH and FHL-1 are useful predictors of the
location of the mutation, proximal when both are absent
and distal to SCR7 when only fH is affected. In this respect,
the fact that the described assays detect both full-length fH
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Figure 4 |Western blotting of plasma samples from
hemolytic uremic syndrome (HUS) patients and their healthy
relatives. Diluted plasma samples were separated on 10%
SDS-polyacrylamide gel electrophoresis gels under non-reducing
conditions, blotted to nitrocellulose, and probed with monoclonal
antibody MBI-7 to detect factor H (fH)-H402. In the Hus90
pedigree, no fH-H402 was detectable in index case (H90),
daughter (90.3), or niece (90.2); FHL-1-H402 was present in each
case. In the Hus29 pedigree, fH-H402 was detectable in the index
case (H29), but at only 12% (by densitometry) of that in the
control sample or in her sister (H29.1); in contrast, FHL-1-H402
levels were increased fivefold (by densitometry) compared with
control or sister samples. Index case H169 had no detectable
fH-H402 but FHL-1-H402 was present at levels similar to controls.
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and the alternative splice product FHL-1 is a considerable
advantage for the detection of occult mutations in fH.
In Hus29, the known point mutation R1210C was shown
by western blot and segregation in the pedigree to be on the
Y402 allele, and hence not responsible for the observed low
expression of fH-H402 allele. The R1210C mutation is
common, results in the formation of disulphide-bonded
albumin–fH complexes that inhibit fluid-phase complement
activation,19 and in a large series has been shown to be
associated with aHUS only in the presence of additional
genetic predisposing factors.26 In Hus29, we contend that
the additional predisposing factor is the inheritance from the
mother of a low expression H402 allele. The sister of
the index case, also a Y402H heterozygote and carrier of the
R1210C mutation, has not inherited the low expression allele
and is therefore likely not at high risk of aHUS, a prediction
only made possible by these novel assays. Critically,
expression of FHL-1-H402 in the index case was increased
fivefold compared with controls, suggesting that a mutation
affecting the differential splicing of the CFH gene was
responsible for the deficit. Although we have undertaken a
thorough search for mutations in the large intronic regions
flanking exons 9, 10, and 11 of the CFH gene, this putative
mutation remains unidentified. Despite the fact that fH and
FHL-1 are products of the same gene, independent regulation
of their expression has been described previously,30 and is
confirmed in this study.
The families described above provide case histories that
prove the value of the variant-specific mAbs and assays we
describe here. Because we have targeted a common poly-
morphism, over 40% of Caucasians are Y402H heterozygous,
these reagents will be useful in the large majority of families.
Here, we showed their value in tracking the disease-associated
allele through a family and, critically, in identifying previously
unsuspected null or low expression alleles, themselves strong
risk factors for the development of aHUS. The specificity of the
mAbs permits unambiguous and rapid identification of occult
low or no expression alleles, independent risk factors for
aHUS that should now be sought in other cohorts.
MATERIALS AND METHODS
Generation and characterization of fH Y402H
variant-specific mAb
Mice were immunized as described before using fusion proteins
comprising fH-Y402 SCRs 6–8 linked to human IgG4 Fc
(fH-Fc).24,31 Hybridoma supernatants were screened for binding
to native fH-H402 and fH-Y402 as described.24 Two hybridomas
producing mAb specific for fH-Y402 were identified, recloned,
isotyped, expanded, and purified as described.24 Specificity was
confirmed by western and dot blotting on pure fH-H402 and
fH-Y402 as described.24 Affinities of the mAb for fH-H402 and
fH-Y402 variants were determined by surface plasmon resonance
on a Biacore T-100 (GE Healthcare, Chalfont, UK) as described.24
Development of fH variant-specific ELISA
Maxisorp (Nunc, Loughborough, UK) plates were coated with
affinity-purified polyclonal rabbit anti-fH (100 ml, 5mg/l) overnight
at 4 1C and blocked with 1% bovine serum albumin in phosphate-
buffered saline. Purified protein standards or serum samples
(diluted 1:3000 in bovine serum albumin or phosphate-buffered
saline, though lower dilutions (1:100) were used to confirm low fH
levels) were added in triplicate and incubated. Wells were washed
and incubated with horseradish peroxidase-labelled Y402-specific or
H402-specific mAb (1mg/l). All incubations were for 1 h, 37 1C
Wells were washed and bound mAb was detected using ortho
phenylene diamine substrate. Absorbance (492 nm) was measured.
Standards were included on each plate and, samples from controls
and patients were randomly assigned to eliminate assay bias. A
nonlinear regression model was used to fit standard curves
generated by ELISA. Total fH (mg/l) was calculated by summing
results for fH-Y402 and fH-H402. Total fH was also measured in an
ELISA, where horseradish peroxidase-labelled non-selective anti-fH
mAb, OX-24, specific for an epitope in SCR5 of fH (Sim et al.32; RB
Sim, personal communication) was used for detection. Detection
limits, working ranges, nr, and assay performance were determined
as described,24 using plasma from 46 local healthy controls (Ethics
approval from the Research and Ethics Committee for Wales. Ref 09/
MRE09/35). Of note, because the capture antibody is polyclonal and
the detecting mAbs identify epitopes in the shared SCRs 1–7, both
the variant-specific and total fH assays will measure the combined
levels of fH and FHL-1. However, none of the assays detect any of
the fH-related proteins because none contain a SCR5-homologous
SCR, and the SCR7-homologous SCR present in FHR-3 alone of
these proteins is not conserved around the Y402H relevant region.
Western and dot-blot assays for fH variants
Western and dot-blot assays were performed as described.24
To confirm the specificity of the mAbs, plasma from patients of
known Y402H variant status was diluted 10-fold, 20-fold, or 40-fold,
and dotted onto nitrocellulose. Separate sets were then probed
with either Y402-specific (MBI-6), H402-specific (MBI-7), or
non-selective (OX-24) mAb. Positive dots were developed using
horseradish peroxidase-labelled anti-mouse IgG and chemilumines-
cent detection. As further proof of specificity, pure fH protein, Y402
and H402 in separate lanes, was run on 10% SDS-polyacrylamide
gel electrophoresis under non-reducing conditions, and transferred
to nitrocellulose. Separate strips were probed either with MBI-6 or
MBI-7, and then developed using horseradish peroxidase-labelled
anti-mouse IgG and chemiluminescent detection.
To test the presence of fH-H402 in patient samples, plasma
(diluted 1:100; 20 ml) was separated on 10% SDS-polyacrylamide gel
electrophoresis under non-reducing conditions, transferred to
nitrocellulose (30min transfer to retain FHL-1 on the membrane),
and probed with MBI-7. Blots were developed as above. To quantify
the relative amounts of fH and/or FHL-1 in and between samples,
the specific bands were analyzed by densitometry.
Genomic analyses
The base change (T1277C) responsible for the Y402H polymor-
phism was analyzed by PCR amplification and sequencing of CFH
exon 9 as described.24 Patients and relatives were screened for
other mutations and polymorphisms in CFH by automatic
sequencing of each exon as described.26
Measurement of fH variants in plasma samples from aHUS
patients and relatives
Patient samples were collected with the approval of the Ethics
Committee of the Consejo Superior de Investigaciones Cientı´ficas
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in accordance with the Declaration of Helsinki. All participants
provided written informed consent. EDTA plasma was stored in
aliquots at 80 1C. Study cases were selected for genetically
determined heterozygosity at the locus encoding the fH-Y402H
polymorphism. Concentrations of the Y402H variants were
measured; index cases were identified with aberrant expression of
either variant. Plasma and DNA were collected from all available
family members of these index cases.
Statistical analysis
Data evaluation was performed using GraphPad Prism software
(version 5.0 for Windows; GraphPad, La Jolla, CA, USA). The
data were checked for normality using the D’Agostino–Pearson
normality test.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by the UK Multiple Sclerosis Society no.
884/08 (to BPM), MRC Project Grant no. 84908 (to CLH and BPM),
Ministerio de Ciencia e Innovacio´n SAF 2005-00913, CIBER de
Enfermedades Raras, and Fundacio´n Renal In˜igo Alvarez de Toledo
(to SRdeC).
REFERENCES
1. Richards A, Goodship J, Goodship T. The genetics and pathogenesis
of haemolytic uraemic syndrome and thrombotic thrombocytopenic
purpura. Curr Opin Nephrol Hypertens 2002; 11: 431–436.
2. Noris M, Remuzzi G. Non-shiga toxin–associated hemolytic uremic
syndrome. In: Zipfel P (ed). Complement and Kidney Disease. Birkha¨user:
Basel, 2005, pp 65–83.
3. Becker S, Fusco G, Fusco J et al. Collaborations in HIV Outcomes
Research/US Cohort. HIV-associated thrombotic microangiopathy
in the era of highly active antiretroviral therapy: an observational study.
Clin Infect Dis 2004; 39: S267–S275.
4. Constantinescu AR, Bitzan M, Weiss LS et al. Non-enteropathic hemolytic
uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;
43: 976–982.
5. Mungall S, Mathieson P. Hemolytic uremic syndrome in metastatic
adenocarcinoma of the prostate. Am J Kidney Dis 2002; 40: 1334–1336.
6. McMinn JR, George JN. Evaluation of women with clinically suspected
thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
during pregnancy. J Clin Apher 2001; 16: 202–209.
7. Dlott JS, Danielson CF, Blue-Hnidy DE et al. Drug-induced thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome: a concise
review. Ther Apher Dial 2004; 8: 102–111.
8. Kind T, Levy J, Lee M et al. Cobalamin C disease presenting as hemolytic-
uremic syndrome in the neonatal period. J Pediatr Hematol Oncol 2002;
24: 327–329.
9. Pirson Y, Lefebvre C, Arnout C et al. Hemolytic uremic syndrome in three
adult siblings: a familial study and evolution. Clin Nephrol 1987; 28:
250–255.
10. Kaplan BS, Papadimitriou M, Brezin JH et al. Renal transplantation in
adults with autosomal recessive inheritance of hemolytic uremic
syndrome. Am J Kidney Dis 1997; 30: 760–765.
11. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E et al.
The human complement factor H: functional roles, genetic variations and
disease associations. Mol Immunol 2004; 41: 355–367.
12. Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional
analyses of membrane cofactor protein (CD46) mutations in atypical
hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017–2025.
13. Kavanagh D, Kemp E, Mayland E et al. Mutations in complement factor I
(IF) predispose to the development of atypical HUS. J Am Soc Nephrol
2005; 16: 2150–2155.
14. Fre´meaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in
complement C3 predispose to development of atypical hemolytic uremic
syndrome. Blood 2008; 112: 4948–4952.
15. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-
function mutations in complement factor B are associated with atypical
hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104: 240–245.
16. Saunders RE, Abarrategui-Garrido C, Fre´meaux-Bacchi V et al. The
interactive factor H-atypical hemolytic uremic syndrome mutation
database and website: update and integration of membrane cofactor
protein and factor I mutations with structural models. Hum Mutat 2007;
28: 222–234.
17. Perkins SJ, Goodship TH. Molecular modelling of the C-terminal domains
of factor H of human complement: a correlation between haemolytic
uraemic syndrome and a predicted heparin binding site. J Mol Biol 2002;
316: 217–224.
18. Esparza-Gordillo J, Jorge EG, Garrido CA et al. Insights into hemolytic
uremic syndrome: segregation of three independent predisposition
factors in a large, multiple affected pedigree. Mol Immunol 2006; 43:
1769–1775.
19. Sa´nchez-Corral P, Perez-Cabalerro D, Huarte O et al. Structural and
functional characterisation of factor H mutations associated with atypical
hemolytic uremic syndrome. Am J Hum Genet 2002; 71: 1285–1295.
20. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C et al. Heterozygous and
homozygous factor H deficiencies associated with hemolytic uremic
syndrome or membranoproliferative glomerulonephritis: report and
genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787–795.
21. Ault BH, Schmidt BZ, Fowler NL et al. Human factor H deficiency.
Mutations in framework cysteine residues and block in H protein
secretion and intracellular catabolism. J Biol Chem 1997; 272:
25168–25175.
22. Schmidt BZ, Fowler NL, Hidvegi T et al. Disruption of disulfide bonds is
responsible for impaired secretion in human complement factor H
deficiency. J Biol Chem 1999; 274: 11782–11788.
23. Edwards AO, Ritter III R, Abel KJ et al. Complement factor H
polymorphism and age-related macular degeneration. Science 2005;
308: 421–424.
24. Hakobyan S, Harris CL, Tortajada A et al. Measurement of factor H variants
in plasma using variant-specific monoclonal antibodies: application to
assessing risk of age-related macular degeneration. Invest Ophthalmol Vis
Sci 2008; 49: 1983–1990.
25. Zipfel PF, Skerka C. FHL-1/reconectin: a human complement and immune
regulator with cell-adhesive function. Immunol Today 1999; 20: 135–140.
26. Martinez-Barricarte R, Pianetti G, Gautard R et al. The complement factor
H R1210C mutation is associated with atypical hemolytic uremic
syndrome. J Am Soc Nephrol 2008; 19: 639–646.
27. Pe´rez-Caballero D, Gonza´lez-Rubio C, Gallardo ME et al. Clustering of
missense mutations in the C-terminal region of factor H in atypical
hemolytic uremic syndrome. Am J Hum Genet 2001; 68: 478–484.
28. Esparza-Gordillo J, Soria JM, Bui A et al. Genetic and environmental
factors influencing the human factor H plasma levels. Immunogenetics
2004; 56: 77–82.
29. Falcao DA, Reis ES, Paixao-Cavalcante D et al. Deficiency of the human
complement regulatory protein factor H associated with low levels of
component C9. Scand J Immunol 2008; 68: 445–455.
30. Friese MA, Hellwage J, Jokiranta TS et al. FHL-1/reconectin and factor H:
two human complement regulators which are encoded by the same
gene are differentially expressed and regulated. Mol Immunol 1999; 36:
809–818.
31. Harris CL, Lublin DM, Morgan BP. Efficient generation of monoclonal
antibodies for specific protein domains using recombinant
immunoglobulin fusion proteins: pitfalls and solutions. J Immunol
Methods 2002; 268: 245–258.
32. Sim E, Palmer MS, Puklavec M et al. Monoclonal antibodies against the
complement control protein factor H (beta 1 H). Biosci Rep 1983; 3:
1119–1131.
788 Kidney International (2010) 78, 782–788
or ig ina l a r t i c l e S Hakobyan et al.: fH variants in atypical hemolytic uremic syndrome
